

Clinical Drug Information

20180326

Overview: Wolters Kluwer Global



- Offices in 40+ Countries
- 19,000 Employees Worldwide
- €4.2 Billion Annual Revenue

Overview: Wolters Kluwer Health



Health

2,900 Employees Worldwide

€1 Billion Annual Revenue

- Lippincott Solutions
- Ovid®

Clinical Software Solutions

- ProVation Medical
- Health Language Engine
- Sentri7

Clinical Effectiveness

- UpToDate ®
- Medi-Span®
- Lexicomp®

Clinical Drug Information

- Facts & Comparisons®
- Emmi®

Overview: ACDS(Advanced Clinical Decision Support)

Medi-Span

- 180,000+ National Drug Codes(NDCs)
- 750K+ price points and 4.8M+ drug attributes
- 35,000+ Pricing updates per year and added 12,000+ NDCs per year
- 5M+ clinical screening records maintained for US and International drugs over 16 Content areas
- 60+ Databases and APIs delivering the content

Lexicomp / Facts&Comparisons

- 41,000+ Drug Information topics
- 7,200+ International Drug Information topics
- 3,500+ In-depth monographs
- 16,700+ Toxicology-related topics
- 520+ Natural Product monographs
- 6,900+ Additional Patient Education topics on drugs (19 languages)

UpToDate

- 24 Specialties
- 10,500+ Clinical topics
- 1,500+ Patient topics
- 6,300+ Physician Authors and Editors
- 5,600+ Drug entries
- 30,000+ Graphics
- 425,000 Links to evidence

Emmi

- 300+ Multimedia programs
- 1,500+ Articles
- 250+ IVR calls
- 15+ Multimodal series
- 200 Programs in multiple languages
- 1,000+ Medical illustrations and animations
- 5,000+ Non-medical illustrations and animations

What is Lexicomp?

Drug database to obtain point of care advice with high quality, 100% evidence-based drug information

- Decide Drug Therapy
- Optimize Drug efficacy - reduce errors
- Promote communication –consistency Info



Wolters Kluwer

Editorial Processes

Two process

- External pharmacist review > validate and qualify the information
- Internal clinical team
  - ✓ Team of pharmacists (+200 specialized pharmacists)
  - ✓ Team of UTD editors, peer reviewers, authors (+6500 world renowned physicians/pharmacists editorial team)
  - ✓ Advanced clinical training (PharmD or PhD)
  - ✓ Typically +10 years of extensive clinical experience
  - ✓ DAILY monitoring & Update
    - Manufacturer announcements, Top Med Journal Publications
    - Regulatory agencies (FDA, Health Canada, etc)
  - ✓ Data Consistency across WK Clinical Effectiveness solutions.

Rigorous Editorial Processes to Ensure Data Accuracy, Reliability, and Consistency

Clinical Drug Information Editorial Process



OUR EDITORIAL PROCESS

Launching New Monographs

- FDA or Health Canada approvals, regulatory, manufacturer, and scientific reports launch the development of new drug monographs.
- Development begins with aggregate sources:
  - Product labeling
  - Base pharmacology studies
  - Clinical trials
- New referential monographs are developed first and then used to synthesize integrated drug data content.
- Medication patient education leaflets and drug interaction information are updated concurrently with core drug information and monographs.

Developing Content

- Data acquisition professionals conduct daily surveillance of industry activity and primary literature so that our information reflects contemporary medical practices and promotes relevance and clarity of content.
- Content synthesized, managed, and reviewed by a team of nearly 150 advanced-degreed clinicians:
  - Full-time, in-house clinical teams include more than 70 pharmacists, as well as physicians, nurses, and medical technologists
- Internal and external contributors discuss unique drug properties.

Ongoing Research

- Further research and regular review of information helps identify relevant medical information (e.g., adverse drug reaction reports, clinical practice guidelines):
  - Medical journals
  - News sources
  - International sites
  - Industry websites (e.g., CDC, pharmaceutical manufacturers)

External Review

- Monographs are reviewed by members of a diverse board of more than 260 external contributors who are specialists and practicing experts in their own therapeutic area, including physicians, nurses, dental professionals, and dieticians.

Clinical Quality Control

- Clinical Quality Control review tests that content works correctly within our software and returns appropriate clinical results.
- Cross-functional team representing content, technology, product management, and implementation employs complex "edge test cases" for which a clinician must verify the results.

Delivery

- Delivery of new content to you:
  - Instant online and mobile publication of newly completed reference monographs
  - Daily, weekly, or monthly updates of new drug data content

Continuous Updating

- Review of clinical literature, regulatory agency reports, and clinical feedback on an ongoing basis to identify new or updated drug information.
- Research conducted at least once weekly to update information pertaining to medication guides, Risk Evaluation and Mitigation Strategies (REMS), and U.S. drug shortages.

Continuous Updating (continued)

- Ongoing review of pharmaceutical manufacturer announcements and publications to find information on:
  - New drug availability
  - New dosage forms
  - Revisions to contraindications, warnings, drug interactions
  - Other labeling changes
- Internal clinical team also monitors available information from the medical science arena:
  - Routine review of published literature within key therapeutic areas
  - Coordinating input related to clinical guidelines and clinical practice based upon contributors' subject matter expertise
- New or revised clinical information discovered during ongoing review prompts updates to existing content, following the same rigorous vetting process.

Lexicomp vs UpToDate Differentiation (More Content)

- Drug Shortages (drug-shortages)
- Medication Patient Education with HCAHPS Considerations (pai)
- REMS Components (remcmp)
- Dosing: Combination Regimens (cbr)
- Calculations (calclist)
- Anatomic Therapeutic Chemical (ATC) Classification (atclist)
- Administration: IV (aiv)
- Administration: Injectable Detail (ivd)
- Administration: Oral (aor)
- Administration: Topical (ato)
- Administration: Subcutaneous (asq)
- Administration: Inhalation (ain)
- Administration: Other (aot)
- Administration: Endotracheal (aet)
- Administration: Intra-arterial (aia)
- Administration: Intracavernous (aic)
- Administration: Intradermal (aidrm)
- Administration: Intraosseous (aio)
- Administration: Intrathecal (ait)
- Administration: Intravaginal (avg)
- Administration: Intravitreal (avt)
- Administration: Ophthalmic (aop)
- Clinical Practice Guidelines (cpg)
- Vesicant/Extravasation Risk (ves)
- Extemporaneously Prepared (exp)
- Level of Evidence Definitions (use-lvl-evidence)
- Use: Unsupported (unsupported-uses-nested)
- Drug of Choice or Alternative for Disease/Syndrome(s) (dcdlist-ext)
- Drug of Choice or Alternative for Organism(s) (dcolist-ext)
- Regimen Use (regimen-use)
- Comparative Efficacy: Powered by Facts & Comparisons (add-comparative-efficacy)
- Class Monographs
- Clinical Practice Guidelines (cpg)
- Allergy and Idiosyncratic Reactions (prrlist)
- Oncology: Emetic Potential (emp)
- Geriatric Considerations (spg)
- Test Interactions (tia)
- Gene Testing Required (genereqlist)
- Gene Testing Recommended (generecmdlist)
- Gene Testing May Be Considered (geneconsdrlist)
- Genes of Interest (goilist-ext)
- Lexicomp Pregnancy & Lactation, In-Depth (add-preg-lac)
- Briggs' Drugs in Pregnancy & Lactation (briggs-list)
- Storage/Stability (sts)
- Preparation for Administration (str)
- Index Terms (synlist)
- Allergy and Idiosyncratic Reactions (prrlist)
- Oncology: Emetic Potential (emp)
- Geriatric Considerations (spg)
- Test Interactions (tia)
- Gene Testing Required (genereqlist)
- Gene Testing Recommended (generecmdlist)
- Gene Testing May Be Considered (geneconsdrlist)
- Genes of Interest (goilist-ext)
- Lexicomp Pregnancy & Lactation, In-Depth (add-preg-lac)
- Briggs' Drugs in Pregnancy & Lactation (briggs-list)
- Storage/Stability (sts)
- Local Anesthetic/Vasoconstrictor Precautions (vap)
- Dental Health Professional Considerations (dcf)
- Effects on Dental Treatment (edt)
- Effects on Bleeding (eob)
- Dental Usual Dosing (dud)
- Related Information (rftlist)
- Pharmacotherapy Pearls (adi)
- Index Terms (synlist)
- Regimen (reg)
- Preparation for Administration (str)
- Comparative Efficacy: Powered by Facts & Comparisons (add-comparative-efficacy)
- Extemporaneously Prepared (exp)
- Level of Evidence Definitions (use-lvl-evidence)
- Use: Unsupported (unsupported-uses-nested)
- Drug of Choice or Alternative for Disease/Syndrome(s) (dcdlist-ext)
- Drug of Choice or Alternative for Organism(s) (dcolist-ext)
- Dental Health Professional Considerations (dcf)
- Effects on Dental Treatment (edt)
- Effects on Bleeding (eob)
- Dental Usual Dosing (dud)
- Related Information (rftlist)
- Regimen (reg)
- Nursing: Physical Assessment/Monitoring (mpa)
- Dental Use (uso)
- Regimen Use (regimen-use)
- Pharmacotherapy Pearls (adi)
- Administration: Otic (aoc)
- Administration: Rectal (arct)
- Vesicant/Extravasation Risk (ves)
- Nursing: Physical Assessment/Monitoring (mpa)
- Dental Use (uso)
- Local Anesthetic/Vasoconstrictor Precautions (vap)
- Class Monographs

Lexicomp vs UpToDate Differentiation (More depth)

藥物內容深度: From Drug Monograph, many in-depth content are not covered in UpToDate. For example: Cisplatin, If you refer to the drug monograph of CISplatin in Lexicomp (see screenshot below), you can see the whole section of Dosing: Combination Regimens is NOT included in UpToDate

Dosing: Combination Regimens

Biliary adenocarcinoma: Gemcitabine-Cisplatin (Biliary Cancer)

Bladder cancer:

- Cisplatin-Docetaxel-Gemcitabine (Bladder)
- Cisplatin-Fluorouracil (Bladder Cancer)
- Cisplatin-Gemcitabine (Bladder)
- CMV (Bladder)
- Dose Dense MVAC (Bladder Cancer)
- MVAC (Bladder)
- PCG (Bladder)

Bone sarcoma (osteosarcoma):

- Ifosfamide-Cisplatin-Epirubicin (Osteosarcoma)
- MAP (Osteosarcoma)

Brain tumors:

- CDDP/VP-16
- COPE

Cervical cancer:

- Bevacizumab-Cisplatin-Paclitaxel (Cervical)
- Cisplatin-Fluorouracil (Cervical Cancer)
- Cisplatin-Gemcitabine (Cervical)
- Cisplatin-Paclitaxel (Cervical Cancer)
- Cisplatin-Topotecan (Cervical Cancer)
- Cisplatin-Vinorelbine (Cervical Cancer)

Endometrial cancer:

- Cisplatin-Doxorubicin (Endometrial)
- Cisplatin-Doxorubicin-Paclitaxel (Endometrial)

Esophageal cancer:

- Cisplatin-Capecitabine (Esophageal Cancer)
- Cisplatin-Fluorouracil (Esophageal Cancer)

Lexicomp Welcome Page



Lexicomp Drug Information Databases

- Lexicomp Adult Drug Information
- Lexicomp Neonatal Drug Information
- FACTS & COMPARISONS
- OFF-LABEL DATABASE
- COMPARATIVE EFFICACY AND ROLE IN THERAPY
- AHFS DI® ESSENTIALS™
- AHFS DRUG INFORMATION®
- MARTINDALE: THE COMPLETE DRUG REFERENCE™
- BRIGGS' DRUGS IN PREGNANCY AND LACTATION
- THE 5-MINUTE CLINICAL CONSULT
- NURSING DRUG INFORMATION
- NATURAL PRODUCTS
- INFECTIOUS DISEASE
- LABORATORY TESTS AND DIAGNOSTIC PROCEDURES
- PHARMACOGENOMICS
- DENTAL DRUG INFORMATION
- GERIATRIC DRUG INFORMATION
- GLOBAL DRUG INFORMATION
- PREGNANCY AND LACTATION INFORMATION
- DRUG ALLERGY AND IDIOSYNCRATIC REACTIONS
- VISUALDX®

Indexes


Lexicomp®
Informar medicamento, doença, NDC ou out
Search
Limit Search to
Feedback
Corporate
User Guide
Logout
Select Interface Language
Recent Documents
Interações
Drug I.D.
Calculators
Drug Comparisons
Trissel's IV Compatibility
Patient Education
Formulary Monograph Service
Toxicology
UpToDate®
More Clinical Tools
Available Indexes
Hospital Formulary (Example Database)
Generic Names
U.S. Brand Names
Charts/Special Topics
Changed Last 7 Days
Pharmacologic/Therapeutic Category
REMS
Restrictions
Prescribing and Access Restrictions
Black Box Warnings
Special Alerts
Lexi-Drugs Multinational
Generic Names
U.S. Brand Names
Canadian Brand Names
Charts/Special Topics
Changed Last 7 Days
Pharmacologic/Therapeutic Category
REMS
All Databases
Print
Help
All Databases
Hospital Formulary (Example Database)
Lexi-Drugs Multinational
Lexi-Drugs Multinational provides clinicians with in-depth information on: Adverse reactions, Canadian brand names, dosing, special alerts, medication safety issues, pharmacodynamics/kinetics, and trade names from more than 100 countries. Lexi-Drugs Multinational contains all monographs from Lexi-Drugs as well as drugs some available outside of the US and Canada. Lexi-Drugs covers various patient populations, as well as the following clinical specialties: Pharmacy, nursing, internal medicine, cardiology, oncology, psychiatry, anesthesiology, and dentistry.
Pediatric and Neonatal Lexi-Drugs
Specifically designed for Pediatricians, other clinicians who work with pediatric patients, or in any situation where pediatric dosing information is required, this database contains detailed guidelines that have been researched and compiled by pediatric specialists. It includes over 900 drugs, with monographs that cover up to 48 fields of information, including very detailed neonatal and pediatric dosing.
AHFS Essentials (Adult and Pediatric)
Derived from the more extensive and detailed AHFS Drug Information, the AHFS DI Essentials database provides a deeper level of actionable drug information and includes off-label uses. This database is ideal for more detailed questions at the point-of-care. The drug monograph content is derived from AHFS Drug Information, a premier source of meticulously evidence-based drug information. Includes information on safe drug use in pregnant and breast-feeding women, off label uses, and an overview of the drug's pharmacologic actions and effects.
AHFS DI (Adult and Pediatric)
This database provides the deepest level of drug information with off-label uses and recommendations from an authoritative source. A recognized Official Compendium by the US Congress, this is the only drug

Search In Lexicomp



Search Result

Drug Monograph



Monograph: Dosing

跟**UpToDate**一樣, **Lexicomp** 藥物專題的內容編排方式的目的是最快讓臨床工作者找到需要的答案或用藥建議，內容分成**2**個層，第一層能給您**70-80%**需要的資訊，如需要更深一層的資訊，可以直接點擊鏈接以進入第二層來獲得更多的資訊. **Ex)** Dosage and Administration in AHFS Essentials for additional information.

用最精簡的文字呈現臨床醫師藥師所需的Dosage數據和資訊。

Dosing根據不同受眾群體來表示，更快速找到答案

Wolters Kluwer

Monograph: Dosing

Warfarin (Lexi-Drugs Multinational)

Navigation Tree

Expand All

- ALERT: US Boxed Warning
- ▸ Brand Names
- International Nonproprietary Names (INN)
- Brazilian Nonproprietary Names (DCB)
- Anatomic Therapeutic Chemical (ATC) Classification
- Pharmacologic Category
- ▾ Dosages
  - Dosing: Adult
  - Dosing: Geriatric
  - Dosing: Pediatric
  - Dosing: Renal Impairment
  - Dosing: Hepatic Impairment
- ▸ Uses
- Clinical Practice Guidelines

Monograph | Images | Adult Patient Education | Pediatric Patient Education

Find in document | Enter text to find... | clear | Jump to Section | Print | Help

Duration of therapy:

Warfarin Duration of Therapy by Indication

Indication	Duration of therapy
AF (including AF and mitral stenosis, AF and stable coronary artery disease) (January 2014)	Indefinite[1]
Bioprosthetic valves in the mitral position (Whitlock 2012)	3 months after valve insertion
Mechanical prosthetic cardiac valves (Whitlock 2012)	Indefinite
Anterior MI with LV thrombus or at high risk for LV thrombus (Vandvik 2012)	3 months after MI
*VTE (*Kearon 2012; Kearon 2016)	
First episode, provoked or unprovoked DVT of the leg or PE (*without* cancer)	3 months minimum or extended therapy[1] may be considered in patients who do not have a high risk of bleeding
Unprovoked second DVT of the leg or PE	Extended therapy[1] is recommended in patients who do not have a high risk of bleeding
In patients with DVT of the leg or PE and *with* cancer **Note:** LMWH is preferred over oral anticoagulation for treatment of patients *with* cancer	Extended therapy[1] is recommended, although high bleeding risk confers a lower grade of recommendation.

[1]Extended therapy is defined as after first 3 months of treatment and with no scheduled stop date. All patients receiving extended or indefinite therapy should be reassessed at periodic intervals for

https://online.lexi.com/lco/action/interact

Monograph: Hazardous Drugs Handling



Monograph: Pregnancy Considerations



Monograph: Nursing Considerations



Monograph: Patient Education (in Chinese)



Monograph: Patient Education (in Chinese)



用問答的方式，列出6-7個病人最常問的問題/或須知，並用簡單的文字回答

Drug Interactions



可搜尋藥物vs食物，藥物vs藥物，藥物vs草藥等的交互作用

Lexicomp有收錄超過550種草藥的monograph

Drug Interactions



Drug Interactions



Drug Interactions

圖一

點擊單獨藥物，可進入所有會此藥物產生交互作用的藥物/草藥/食物monograph，如下圖二



圖二



點擊可再進入Warfarin跟Vorapaxar的交互作用monograph

Drug Interactions

Lexicomp也有收錄3種藥物同時用藥會產生的交互作用，如下：



點擊進入3種藥物同時用藥的交互作用詳細說明，請參閱下一張投影片！

更新日期: 當有新的臨床藥學發現，Lexicomp會及時更新

Drug Interactions

Search | Interaction Analysis | Interaction Monograph

Print | Hel

Title Angiotensin-Converting Enzyme Inhibitors / Angiotensin II Receptor Blockers

Dependencies:

- **Additional drug/group**: Routine combined use of an angiotensin converting enzyme inhibitor, angiotensin II blocker, and aldosterone antagonist is not recommended for patients with heart failure with reduced ejection fraction.

Risk Rating D: Consider therapy modification

Summary Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Angiotensin II Receptor Blockers may increase the serum concentration of Angiotensin-Converting Enzyme Inhibitors. **Severity** Moderate **Reliability Rating** Fair

Patient Management US labeling states that concurrent use of telmisartan and ramipril is specifically not recommended and Canadian labeling states that irbesartan and eprosartan are contraindicated for use with ACE Inhibitors in patients with diabetic nephropathy. It is not clear if any other combination of an ACE inhibitor and an ARB would be any safer. If such a combination must be used, monitor patients extra closely for a greater-than-expected response to the combination, including monitoring of blood pressure, renal function, and potassium concentrations.

Angiotensin-Converting Enzyme Inhibitors Interacting Members Alacepril; Benazepril; Captopril; Cilazapril; Enalapril; Enalaprilat; Fosinopril; Imidapril; Lisinopril; Moexipril; Perindopril; Quinapril; Ramipril; Trandolapril; Zofenopril

Angiotensin II Receptor Blockers Interacting Members Azilsartan; Candesartan; Eprosartan; Fimasartan; Irbesartan; Losartan; Olmesartan; Telmisartan; Valsartan

Discussion The risk of developing hyperkalemia or acute kidney injury were both significantly increased among subjects randomized to combined therapy with losartan (100 mg/day) and lisinopril (10 mg to 40 mg daily) as compared to subjects randomized to losartan monotherapy in a clinical trial of 1448 subjects with type 2 diabetes and nephropathy.[1] Hyperkalemia was present at a frequency of 6.3 events per 100 person-years with combination therapy versus 2.6 events per 100 person-years with losartan monotherapy, and acute kidney injury was present at a frequency of 12.2 events per 100 person-years versus 6.7 events per 100 person-years with losartan monotherapy.

Subject randomly assigned to the combination of ramipril and telmisartan (n=8502) as part of the large ONTARGET clinical trial were more likely to discontinue study drug, experienced more signs/symptoms of hypotension, experienced hyperkalemia, or had a worsening of renal function impairment as compared to subjects assigned to either ramipril or telmistartan alone (n=8576 and n=8542, respectively).[2] Additionally, as described in the telmisartan prescribing information, the average ramipril AUC and maximum serum concentration (Cmax) were increased 2.1-fold and 2.3-fold, respectively, when ramipril (10 mg daily) and telmisartan (80 mg daily) were administered concurrently in healthy volunteers.[3] Concentrations of the active metabolite ramiprilat were similarly increased with concurrent telmisartan (by an average of 1.5- and 2.4-fold for AUC and Cmax). Telmisartan AUC and Cmax were slightly decreased (by 16% and 31%) with the combination.

Drug Comparisons

Compared to Micromedex, Lexicomp Drug Comparion can compare 4 drugs at the same time, and also can customize the field of comparisons. Except clinical use of comparing drugs, also very useful when evaluating new drugs for management purpose.



Can choose the fields being compared

Drug Comparison



Drug Comparisons (Monograph View)



Drug Comparisons (Data View)

Give clear presentation of comparison, if need to know more detail, just click Into the hyperlink; for example, if I want to know more about one of the adverse effects of Rosuvastatin – Arthraigia, just simply click it. See next slide!!!



Drug Comparisons (Data View)

Data View

Give the overall background of this particular adverse reaction of Rosuvastatin.

Selected Drugs | Search | Results | Detail

Print

Drugs

- Acetaminophen ER Oral
- Aspirin 81 Oral
- Rosuvastatin Calcium Oral
- Warfarin Sodium Oral

Available Sections

- Adverse Effects
- Indications
- Drug-Pregnancy
- Drug-Lactation
- Contraindications/Precautions
- Drug-Drug Interactions
- Drug-Food Interactions
- Drug-Alcohol Interactions

Adverse Effects: Rosuvastatin Calcium Oral: Arthralgia

Severity Level	Incidence	Side Effect Type	Onset	Documentation Level
☐ Major	■ **COMMON**	☐ Allergic	☐ Delayed	☐ Established
■ **MODERATE**	☐ More Frequent	☐ Carcinogenic	☐ Intermediate	☐ Probable
☐ Minor	☐ Less Frequent	☐ Long-Term Use	☐ Rapid	■ **POSSIBLE**
	☐ Rare	■ **OTHER**	■ **VARIED**	☐ Doubtful
	☐ Not specified	☐ Overdose	☐ Not specified	
		☐ Teratogenic		
		☐ Toxic		
		☐ Withdrawal		

Trissel´s IV Compatibility

Trissel's™ 2 Clinical Pharmaceutics Database (created by Lawrence A. Trissel)

Selected Items

Click on the drug name to view compatibility results for a single drug or for a drug properties monograph.

Drugs

- Cefazolin [Cefazolin sodium]
- Ciprofloxacin
- Warfarin sodium

Solutions

- Lactated Ringers Intravenous [LR (Lactated Ringer's)]

Analyze | Clear

Search | Compatibility Chart | Details

Compatibility Chart

Click on the drug/drug and/or drug/solution result to access supporting information from compatibi

- C Indicates compatibility for this method
- U Uncertain or variable for this method
- I Indicates incompatiblity for this method
- No data for administration methods chosen

Drugs	Cefazolin sodium	Ciprofloxacin	Warfarin sodium
Cefazolin sodium			C Y-Site
Ciprofloxacin			I Y-Site
Warfarin sodium	C Y-Site	I Y-Site	
Solutions			
LR (Lactated Ringer's)	C Solution C Y-Site	C Solution C Y-Site	U Solution

Click to see more details

Details

You searched on the following parameters:

Administration Method:	Y-Site
Drugs:	Ciprofloxacin , Warfarin sodium
Vehicles:	none
Solutions:	none

Results: 2 incompatible study result(s). Click on a study to view details.

Study	Drug 1	Vehicle 1	Drug 2	Vehicle 2	Solution	Finding
Study 1	Ciprofloxacin 2 mg/mL	D5W (Dextrose 5% in Water)	Warfarin sodium 2 mg/mL	Reconstituted solution undiluted		I Incompatible
Study 2	Ciprofloxacin 2 mg/mL	D5W (Dextrose 5% in Water)	Warfarin sodium 2 mg/mL	Reconstituted solution undiluted		I Incompatible

Trissel´s IV Compatibility

You can analyze as many drugs as you like. See example below. Search for 6 drugs mixed in 2 solutions or even more !!!

Trissel's™ 2 Clinical Pharmaceutics Database (created by Lawrence A. Trissel)

Selected Items

Click on the drug name to view compatibility results for a single drug or for a drug properties monograph.

Drugs

- Amoxicillin sodium
- Cefazolin [Cefazolin sodium]
- Ciprofloxacin
- Digoxin
- Dopamine hydrochloride
- Gadobenate dimeglumine
- Warfarin sodium

Solutions

- Lactated Ringers Intravenous [LR (Lactated Ringer's)]
- Sodium Chloride [NS (Normal Saline) - Sodium Chloride 0.9%]

Analyze | Clear

Search | Compatibility Chart | Details

All methods

Click on the drug/drug and/or drug/solution result to access supporting information from compatibility studies

C Indicates compatibility for this method
U Uncertain or variable for this method
I Indicates incompatiblity for this method
No data for administration methods chosen

Drugs	Amoxicillin sodium	Cefazolin sodium	Ciprofloxacin	Digoxin	Dopamine hydrochloride	Gadobenate dimeglumine	Warfarin sodium
Amoxicillin sodium			I Admixture				
Cefazolin sodium				C Y-Site	I Y-Site		C Y-Site
Ciprofloxacin	I Admixture			C Y-Site	C Y-Site C Admixture		I Y-Site
Digoxin		C Y-Site	C Y-Site		C Y-Site		
Dopamine hydrochloride		I Y-Site	C Y-Site C Admixture	C Y-Site			C Y-Site
Gadobenate dimeglumine							

Calculators (over 190 medical / pharmacologicl calculators)



Calculators (over 190 medical / pharmacologicl calculators)



Calculators (over 190 medical / pharmacologicl calculators)



Calculators (over 190 medical / pharmacologicl calculators)



This function gives you most commonly used drugs / dosages / instrunction notes with patients in Life Supports

Calculators (over 190 medical / pharmacologicl calculators)



Wolters Kluwer

Toxicology: Lexi-Tox



Lexi-Tox


Lexi-Tox™
Feedback Corporate User Guide Logout
Enter poison, antidote, household product, e
Search
Select Interface Language
Recent Documents
Drug I.D. Calculators Drug Comparisons Trissel's IV Compatibility Formulary Monograph Service UpToDate® Leave Toxicology Mode
Search Results : "warfarin" in Toxicology
All Results
Print Help
Lab Tests and Diagnostic Procedures
Warfarin Gene Mutations
Warfarin Level
Warfarin Management Applies to Prothrombin Time and INR Updated 11/8/16
Lexi-Tox
Warfarin Updated 2/7/17
Terms & Conditions - Disclaimer
© 2017 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All Rights Reserved.
Jump to field
Additional Information
Brand Names: Canada
Brand Names: US
Breast-Feeding Considerations
CAS Registration
Clinical Presentation
Complications of Exposure
Diagnosis
Dosage Forms
Hazardous Drugs Handling Considerations
Index Terms
Laboratory Testing/Diagnostic Procedures
Mechanism of Toxicity
Name
Patient Disposition
http://online.lexi.com/lco/action/doc/retrieve/docid/lexier/13030137hl=warfarin

Lexi-Tox: Treatment Antidote




Lexi-Tox™
Enter poison, antidote, household product, e
Search
Feedback
Corporate
User Guide
Logout
Select Interface Language
Recent Documents
Drug I.D.
Calculators
Drug Comparisons
Trissel's IV Compatibility
Formulary Monograph Service
UpToDate®
Leave Toxicology Mode
Warfarin (Lexi-Tox)
Navigation Tree
Expand All
Procedures
Treatment
Treatment: Stabilization
Treatment: Decontamination
Treatment: Antidote(s)
Treatment: Pharmacologic Supportive Therapy
Patient Disposition
Pharmacodynamics/Kinetics
Hazardous Drugs Handling Considerations
Complications of Exposure
Breast-Feeding Considerations
Additional Information
Dosage Forms
References
Warfarin
Jump to Section
Print
Help
Breast-Feeding Considerations Breast-feeding women may be treated with warfarin. Based on available data, warfarin does not pass into breast milk. Women who are breast-feeding should be carefully monitored to avoid excessive anticoagulation. According to the American College of Chest Physicians (ACCP), warfarin may be used in lactating women who wish to breast-feed their infants (Bates, 2012). Monitor nursing infants for bruising or bleeding (per manufacturer).
Additional Information Optimal care decisions are made based upon specific patient details. Consider consultation with a poison control center. To reach poison control centers in the United States and its territories, call 1-800-222-1222.
Dosage Forms
Tablet, Oral:
Coumadin: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, 10 mg
Jantoven: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, 10 mg
Generic: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, 10 mg
References
American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Position paper: cathartics. J Toxicol Clin Toxicol. 2004;42(3):243-253 [PubMed 15362590]
American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Position paper: ipecac syrup. J Toxicol Clin Toxicol. 2004;42(2):133-143 [PubMed 15214617]
American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention. Poison treatment in the home. Pediatrics. 2003;112(5):1182-1185 [PubMed 14595067]
Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133(6 Suppl):160S-198S [PubMed 18574265]

Drug MSDS

Material Safety Data Sheets (MSDS) for Drugs

HOME ABOUT THIS DATABASE RELATED RESOURCES CONTACT LOGOUT

Why this database?

The Occupational Safety & Health Administration (OSHA) of the U.S. Department of Labor requires all employers that formulate, stock or use products that contain hazardous chemicals in their workplaces to provide employees with access to Safety Data Sheets (SDS) if employees could potentially be exposed to hazardous chemicals contained in those products. This database was initiated in September 2014 by DeLima Associates of McLean, Virginia (USA) in response to a need for a database of Safety Data Sheets for FDA-Approved drugs. While OSHA requires SDS to be provided by manufacturers for all FDA-Approved drugs, there are some exceptions based on form of drug and potential administration of drug.

The format and content of Material Safety Data Sheets (MSDS) are based on OSHA's Hazard Communication Standards of 1994. However, as of June 15, 2015, manufacturers will be required to provide "Safety Data Sheets" (SDS) with format and content to be consistent with the United Nations Globally Harmonized System of Classification and Labelling of Chemicals (GHS). The deadline for providing GHS-compliant SDS is June 15, 2015. We will replace MSDS in this database with SDS as soon as drug manufacturers develop new safety data sheets for their products.

The database was launched with over 450 safety data sheets for 275 Principal Ingredients contained in drugs produced by over 40 manufacturers. The database now contains 1,100 safety data sheets for over 340 Principal (Active) Ingredients contained in drugs produced by over 120 manufacturers.

Authorized users may search for Safety Data Sheets by drug trade name, principal ingredient or manufacturer name.

FIND SAFETY DATA SHEETS

Search Alphabetically

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

OR

MSDS Drug Trade Name Search

>

Drug Name starting with Drug Name containing



List of 7 Drugs

DRUG NAME	FORM	MANUFACTURER
Warfarin	Solid	Cayman Chemical Company
Warfarin	Tablet	Taro Pharmaceuticals USA Inc.
Warfarin Sodium	Tablet	Spectrum Lab Products
Warfarin Sodium Tablets	Tablet	Barr Laboratories, Inc. Div. of Teva Pharmaceuticals
Warfarin Sodium Tablets	Tablet	Zydus Pharmaceuticals USA Inc.
Warfarin Sodium Tablets-Waiver Letter	Tablet	Citron Pharma
Warfarin-SDS Waiver Letter	Tablet	Amneal Pharmaceuticals

Drug MSDS

Material Safety Data Sheets (MSDS) for Drugs

HOME ABOUT THIS DATABASE RELATED RESOURCES CONTACT LOGOUT

Print With Pdf | Print With Google Doc

SAFETY DATA SHEET(SDS) FOR : Warfarin

MANUFACTURER : Taro Pharmaceuticals USA Inc.

SECTION 1: PRODUCT IDENTIFICATION

PRODUCT NAME: **Warfarin Sodium Tablets USP*** **FORMULA:** $C_{19}H_{15}NaO_4$

CAS #: **129-06-6** **M.W.:** **330.31**

* Multiple strengths. See the table below for each Strength, Appearance, and Product Number

Strength	Appearance	Product Number
1mg	Pink, flat beveled, capsule shaped tablet, scored and engraved "1" on one side, and engraved with "WARFARIN" on the top of "TARO" on the other side.	51672-4027
2mg	Lavender flat beveled, capsule shaped tablet, scored and engraved "2" on one side, and engraved with "WARFARIN" on the top of "TARO" on the other side.	51672-4028
2.5mg	Green, flat beveled, capsule shaped tablet, scored and engraved "2 1/2" on one side, and engraved with "WARFARIN" on the top of "TARO" on the other side.	51672-4029
3mg	Tan, flat beveled, capsule shaped tablet, scored and engraved "3" on one side, and engraved with "WARFARIN" on the top of "TARO" on the other side.	51672-4030
4mg	Blue, flat beveled, capsule shaped tablet, scored and engraved "4" on one side, and engraved with "WARFARIN" on the top of "TARO" on the other side.	51672-4031
5mg	Peach, flat beveled, capsule shaped tablet, scored and engraved "5" on	51672-4032


Lexicomp
Feedback
Corporate
User Guide
Logout
Select Interface Language
Recent Documents
Interações
Drug I.D.
Calculators
Drug Comparisons
Trissel's IV Compatibility
Patient Education
Formulary Monograph Service
Toxicology
UpToDate®
More Clinical Tools
Help
Lexicomp Online
Limit Search to
Informar medicamento, doença, NDC ou out
Search
Explore by General Category:
Medicamentos
Doenças
Toxicologia
Recursos do Paciente
Laboratório
Medicamentos Internacionais
Special Alerts
Chlorhexidine Gluconate: Chlorhexidine Safety Review
Asparaginase (Erwinia): Erwinase Safety Alert
Enoxaparin: Low Molecular Weight Heparins Safety Alert
Dalteparin: Low Molecular Weight Heparins Safety Alert
Training Videos
Quick Reference Guide
Product Updates
Terms & Conditions
Disclaimer
Wolters Kluwer

More Tools - Tall Man Letters > LASA



More Tools>BEER Criteria



Lexicomp Mobile Solution

- Lexicomp Mobile(行動版)是我們客戶非常推崇試用的產品，我強烈建議藥師試用看看，
- 行動裝置試用設置，請參閱以下鏈接:
- http://www.wolterskluwercdi.com/drug-reference/apps/free-trial/
- Contain all drug monographas, databases (except Martindale) and modules – allow clinicians to access to clinical drug information anytime anywhere!!!

Lexicomp Mobile Solution



Platform

Choose your platform:

- iPhone/iPad/iPod touch
- Android

選擇平台

Follow these instructions for iPhone, iPod touch, & iPad

STEP 1 - CREATE A LEXICOMP ACCOUNT

1. Visit http://www.lexi.com/account
2. Click on the **Create Account** button to create your new Lexicomp account. Enter your registration information and click **Create Account**.

STEP 2 - MOBILE APP INSTALLATION

1. On your iOS device, tap on the **App Store** icon and search for **Lexicomp**.
2. Select **Lexicomp** and tap **Get** or **Free**, then **Install**, or the **small cloud with a downward arrow**, and enter your iTunes password (if prompted) and tap **OK**.
3. Open the **Lexicomp** app on your device.
4. Please read the license agreement and tap **Accept**.
5. Enter your email and password and tap **Sign In**. If you forgot your password, click Forgot Password.
6. When prompted, activate your 30 day demo.
7. Place check marks next to the databases you wish to install, or tap **Select All** and then tap **Update**.
8. If prompted, tap **OK**.
9. After the update is complete, tap the Home icon in the lower right corner.
10. Select an icon to begin accessing your Lexicomp Mobile App demo.

按照安裝步驟進行安裝

Wolters Kluwer


Thank you!
Lexicomp®
Wolters Kluwer